Dr. David "Doc" Eifrig
Wed, Feb 18, 2026|Dr. David "Doc" Eifrig

Don't Count Software Out Just Yet

The message the market sent while obliterating software stocks around the world this month is unmistakable...

No sector is safe from a sudden reset or quick repricing.

The sell-off started a couple weeks ago when artificial-intelligence ("AI") company Anthropic released new features for its Claude Cowork tool. The groundbreaking AI agent can automate tasks for data analysis, marketing, sales, and legal work that previously could only be done with software.

Now, the market thinks that AI will replace a lot of software offerings.

That concern is what prompted a huge selling spree and sent many software stocks down to recent lows...

Take FactSet Research Systems (FDS), for example. FactSet consolidates market data to provide financial insights for investment managers, hedge funds, and investment bankers.

About 75% of the top 50 global investment banks use FactSet. And 95 of the top 100 asset managers use it as well.

Here at Stansberry Research, a lot of analysts use FactSet every day to help with their equity research. And just about every analyst I talk to says that they cannot imagine a world where they would cancel their FactSet subscription.

Overall, FactSet is a business well entrenched in the financial world. The data the company provides is absolutely essential for most professionals' day-to-day work. But the market doesn't care...

It's worried that AI agents will soon be able to do the heavy lifting of data research for free... or at least for a fraction of what FactSet charges.

As a result, FactSet is down more than 60% since its high in late 2024. Take a look...

And even a blue chip like S&P Global (SPGI) has been caught in the crossfire. Some investors believe the company is doomed because its data business will be replaced by AI.

This is despite the company also running the famed S&P 500 Index – which is synonymous with "the market" – and having one of the biggest moats of any business in the world with its bond-rating division.

S&P Global is off its highs by 27%. You can see the sharp drop-off below...

Software companies like Adobe (ADBE) and LegalZoom (LZ) are also near lows. Plus, the iShares Expanded Tech-Software Sector Fund (IGV) has shed 31% from its highs.

We could go on and on. This sell-off has claimed a long list of victims. But there's one important thing for you to remember throughout the chaos...

Just because investors are panicking about AI replacing software doesn't mean they're 100% right.

The market is currently in a "shoot first, ask questions later" phase. And a lot of quality software companies that are not going to be replaced by AI are being thrown out with the bathwater.

Yes, there are going to be software businesses that become obsolete because of AI. But many will be just fine since they'll use AI to keep their market share.

Even Nvidia (NVDA) CEO Jensen Huang agrees with this. He recently pushed back against the market panic and said that AI replacing software tools is "illogical" because AI still depends on software infrastructure to function.

So I think there's going to be a massive buying opportunity for many of the best software names.

In my Retirement Millionaire newsletter, we're waiting for the dust to settle. I've talked before about how it's never the best strategy to try to catch a falling knife. Even if a business is ultra-cheap, it can always get cheaper.

The best investors wait for an uptrend to buy beaten-down companies. That's what we're doing with software stocks.

We're very excited to add a couple of high-quality names to our portfolio at basement prices... when the time is right.

In the meantime, you can still join us at Retirement Millionaire to gain access to the best investment ideas today. We're constantly poring through the market to uncover solid, cash-generating businesses with long-term growth potential.

Our focus isn't on hype or fleeting trends... It's on building a portfolio of resilient companies that can compound your wealth steadily over time. You can learn more here.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
February 18, 2026

Read Full Article

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Read Full Bio
Back to Top